Metagenomi Therapeutics, Inc.
MGX
$1.16
-$0.01-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -27.48M | -23.06M | -22.53M | -20.39M | -19.91M |
| Total Depreciation and Amortization | 1.27M | 1.28M | 1.30M | 1.32M | 1.34M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.06M | 3.53M | 3.93M | 3.45M | 5.26M |
| Change in Net Operating Assets | 2.64M | -2.92M | -6.25M | -5.64M | -7.94M |
| Cash from Operations | -19.51M | -21.18M | -23.55M | -21.25M | -21.25M |
| Capital Expenditure | -125.00K | -25.00K | -85.00K | -74.00K | -127.00K |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 0.00 | 37.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 33.29M | 4.01M | 32.45M | 27.44M | 19.16M |
| Cash from Investing | 33.17M | 3.99M | 32.37M | 27.36M | 19.07M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 74.00K | -- | 93.00K | 0.00 | 109.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.00K | -27.00K | -19.00K | -187.00K | -275.00K |
| Cash from Financing | 67.00K | -27.00K | 74.00K | -187.00K | -166.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 13.72M | -17.22M | 8.89M | 5.92M | -2.35M |